Darzalex(r)V (daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Ineligible for Transplant (Updated on December 10, 2019)

Source :: Plus Company Updates. December 11, 2019
Publication Year :: 2019
Abstract: BEERSE: Janssen has issued the following news release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today overall survival (OS) results from the Phase 3 ALCYONE study, which showed [...]

Subjects :: Johnson & Johnson
Multiple myeloma -- Patient outcomes -- Care and treatment
Daratumumab
Pharmaceutical industry
Death
Prednisone
Operating systems (Software)
Glucocorticoids
Bortezomib
General interest
News, opinion and commentary
Darzalex (Medication)

Tools